The Medicines Patent Pool has set up sublicense agreements with four manufacturers to produce generic versions of Novartis’ cancer drug Tasigna, as part of an ongoing effort to make access to medicines more equitable.
The UN-backed agency announced the news Thursday, saying that Indian generics makers Eugia, Hetero and Dr. Reddy’s Laboratories — along with Indonesia company BrightGene — can manufacture and supply generic versions of nilotinib, which was first approved by the FDA to treat chronic myeloid leukemia in 2007.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters